share_log

四環醫藥：截至二零二三年十二月三十一日止年度的全年業績公告

SIHUAN PHARM: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023

香港交易所 ·  Mar 28 00:17
Summary by Moomoo AI
四環醫藥控股集團有限公司公布截至2023年12月31日止年度全年業績，總收益約為人民幣1,860.5百萬元，較去年同期下降14.7%。醫美產品收益顯著增長200.3%，達人民幣449.9百萬元，主要得益於疫情管控放開及消費需求回暖。仿製藥收益則下降29.0%，至人民幣1,398.8百萬元，受集採降價及監控目錄影響。創新藥及其他藥品收益大幅下降80.6%，至人民幣11.8百萬元，因部分原料藥公司剝離所致。毛利率略有提升至69.6%，研發開支下降38.3%，至人民幣577.7百萬元。經營溢利為人民幣161.7百萬元，去年同期為虧損。財務開支增加至人民幣269.3百萬元，所得稅開支減少至人民幣96.4百萬元。全年虧損約為人民幣257.7百萬元，較去年大幅減少。公司擁有人應佔虧損為人民幣54.0百萬元，非控股權益應佔虧損為人民幣203.7百萬元。董事會不建議派發末期股息。
四環醫藥控股集團有限公司公布截至2023年12月31日止年度全年業績，總收益約為人民幣1,860.5百萬元，較去年同期下降14.7%。醫美產品收益顯著增長200.3%，達人民幣449.9百萬元，主要得益於疫情管控放開及消費需求回暖。仿製藥收益則下降29.0%，至人民幣1,398.8百萬元，受集採降價及監控目錄影響。創新藥及其他藥品收益大幅下降80.6%，至人民幣11.8百萬元，因部分原料藥公司剝離所致。毛利率略有提升至69.6%，研發開支下降38.3%，至人民幣577.7百萬元。經營溢利為人民幣161.7百萬元，去年同期為虧損。財務開支增加至人民幣269.3百萬元，所得稅開支減少至人民幣96.4百萬元。全年虧損約為人民幣257.7百萬元，較去年大幅減少。公司擁有人應佔虧損為人民幣54.0百萬元，非控股權益應佔虧損為人民幣203.7百萬元。董事會不建議派發末期股息。
Four Circle Pharmaceutical Holdings Group Limited announced its annual results for the year ended 31 December 2023 with total revenue of approximately RMB1,860.5 million, down 14.7% from the same period last year. Medical and cosmetic product revenue grew by a remarkable 200.3% to RMB449.9 million, mainly driven by pandemic control liberalization and warming consumer demand. Pharmaceutical revenue fell 29.0% to RMB1,398.8 million, impacted by lower collection prices and monitoring catalogs. Revenue from innovative pharmaceuticals and other pharmaceuticals fell sharply by 80.6% to RMB11.8 million, driven by the shedding of some raw material pharmaceutical companies. Gross profit rose slightly to 69.6% and R&D expenses decreased 38.3% to RMB577.7 million. Operating profit was RMB161.7 million and a loss for the same period last year. Financial expenses increased to RMB269.3 million and income tax expenses decreased to RMB96.4 million. The full-year loss was about RMB257.7 million, a significant decrease from last year. Company owners accounted for a loss of RMB54.0 million and a loss of non-controlling interests of RMB203.7 million. The Board of Directors does not recommend a final dividend.
Four Circle Pharmaceutical Holdings Group Limited announced its annual results for the year ended 31 December 2023 with total revenue of approximately RMB1,860.5 million, down 14.7% from the same period last year. Medical and cosmetic product revenue grew by a remarkable 200.3% to RMB449.9 million, mainly driven by pandemic control liberalization and warming consumer demand. Pharmaceutical revenue fell 29.0% to RMB1,398.8 million, impacted by lower collection prices and monitoring catalogs. Revenue from innovative pharmaceuticals and other pharmaceuticals fell sharply by 80.6% to RMB11.8 million, driven by the shedding of some raw material pharmaceutical companies. Gross profit rose slightly to 69.6% and R&D expenses decreased 38.3% to RMB577.7 million. Operating profit was RMB161.7 million and a loss for the same period last year. Financial expenses increased to RMB269.3 million and income tax expenses decreased to RMB96.4 million. The full-year loss was about RMB257.7 million, a significant decrease from last year. Company owners accounted for a loss of RMB54.0 million and a loss of non-controlling interests of RMB203.7 million. The Board of Directors does not recommend a final dividend.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more